Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143

BACKGROUND: The phase 1 cohorts (1c+1d) of CheckMate 143 (NCT02017717) evaluated the safety/tolerability and efficacy of nivolumab plus radiotherapy (RT) ± temozolomide (TMZ) in newly diagnosed glioblastoma. METHODS: In total, 136 patients were enrolled. In part A (safety lead-in), 31 patients (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Omuro, Antonio, Reardon, David A, Sampson, John H, Baehring, Joachim, Sahebjam, Solmaz, Cloughesy, Timothy F, Chalamandaris, Alexandros-Georgios, Potter, Von, Butowski, Nicholas, Lim, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989388/
https://www.ncbi.nlm.nih.gov/pubmed/35402913
http://dx.doi.org/10.1093/noajnl/vdac025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989388/
https://www.ncbi.nlm.nih.gov/pubmed/35402913
http://dx.doi.org/10.1093/noajnl/vdac025

Ejemplares similares